Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

NCT07023861 is registered in ClinicalTrials.gov with Affiliated Hospital of Jiangnan University as lead sponsor.

NCT NCT07023861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07023861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
Lead sponsor
Affiliated Hospital of Jiangnan University
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
July 1, 2025
Completion date
December 1, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastric cancer (gc), urothelial carcinoma (uc)